Iomazenil

Iomazenil
Clinical data
Other names	Ro 16-0154
Identifiers
	IUPAC name ethyl 7-iodanyl-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate;
CAS Number	127985-21-1 ; 127396-36-5 (123I);
PubChem CID	65959;
ChemSpider	59362;
UNII	7DVX185FLQ; 123I: B851121553;
ChEMBL	ChEMBL2105020;
CompTox Dashboard (EPA)	DTXSID00155549 ;
Chemical and physical data
Formula	C15H14123IN3O3
Molar mass	407.290 g/mol
3D model (JSmol)	Interactive image;
	SMILES CCOC(=O)c1c2n(cn1)-c3cccc(c3C(=O)N(C2)C)I;
	InChI InChI=1S/C15H14IN3O3/c1-3-22-15(21)13-11-7-18(2)14(20)12-9(16)5-4-6-10(12)19(11)8-17-13/h4-6,8H,3,7H2,1-2H3/i16-4; Key:FRIZVHMAECRUBR-KIWWSDKQSA-N;

Iomazenil (also known as Ro16-0154, INN, USAN; benzodine) is an antagonist and partial inverse agonist of benzodiazepine and a potential treatment for alcohol use disorder. The compound was introduced in 1989 by pharmaceutical company Hoffmann-La Roche as an Iodine-123-labelled SPECT tracer for imaging benzodiazepine receptors (GABA_A receptors) in the brain. Iomazenil is an analogue of flumazenil (Ro15-1788).^[1]

^ Höll K, Deisenhammer E, Dauth J, Carmann H, Schubiger PA (1989). "Imaging benzodiazepine receptors in the human brain by single photon emission computed tomography (SPECT)". International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology. 16 (8): 759–63. doi:10.1016/0883-2897(89)90158-x. PMID 2559905.